BackgroundEtoposide-platinum doublet therapy has been the American standard first-line management for patients with small cell lung cancer for more than a decade. In the 1990s, Japanese investigators developed a regimen of irinotecan-cisplatin for extensive-stage patients and, in one head-to-head trial, the irinotecan therapy produced a statistically significant survival advantage compared with etoposide and cisplatin. We were interested in how American oncologists integrate clinical trial data into their current prescribing practices and studied case-based prescribing recommendations as a surrogate for current clinical practice. We evaluated Network for Medical Communications and Research data from 7 years of live physician meetings to ass...
Introduction:A prespecified analysis of the large, randomized, phase III study in advanced non-small...
IntroductionWe conducted a phase II study of combination chemotherapy with irinotecan (CPT) and cisp...
Background:Lung cancer remains a leading cause of cancer-related mortality in North America. Despite...
BackgroundEtoposide-platinum doublet therapy has been the American standard first-line management fo...
Introduction:We sought to determine the efficacy of using both irinotecan- and etoposide-containing ...
IntroductionTo determine whether irinotecan maintenance therapy in extensive disease-small cell lung...
BACKGROUND: A Phase II trial of irinotecan and cisplatin (IP) with early concurrent radiotherapy was...
As a dose-response relationship has been suggested for cisplatin, it appeared attractive to explore ...
Background:To determine the recommended dose and evaluate the response rate and toxicity of triplet ...
BackgroundSequential administration of platinum-based doublet therapy and then a taxane may reduce t...
AbstractCisplatin must be considered the treatment standard for lung cancer chemotherapy, whatever t...
IntroductionSuperiority of camptothecin regimens over etoposide—both combined with platinum analogs—...
BackgroundDose intensity and dose density of first line Platinum and Etoposide (PE) do not influence...
Background:Irinotecan and cisplatin individually are active in non-small cell lung carcinoma (NSCLC)...
IntroductionWe undertook this phase II study to measure postoperative drug delivery and toxicity of ...
Introduction:A prespecified analysis of the large, randomized, phase III study in advanced non-small...
IntroductionWe conducted a phase II study of combination chemotherapy with irinotecan (CPT) and cisp...
Background:Lung cancer remains a leading cause of cancer-related mortality in North America. Despite...
BackgroundEtoposide-platinum doublet therapy has been the American standard first-line management fo...
Introduction:We sought to determine the efficacy of using both irinotecan- and etoposide-containing ...
IntroductionTo determine whether irinotecan maintenance therapy in extensive disease-small cell lung...
BACKGROUND: A Phase II trial of irinotecan and cisplatin (IP) with early concurrent radiotherapy was...
As a dose-response relationship has been suggested for cisplatin, it appeared attractive to explore ...
Background:To determine the recommended dose and evaluate the response rate and toxicity of triplet ...
BackgroundSequential administration of platinum-based doublet therapy and then a taxane may reduce t...
AbstractCisplatin must be considered the treatment standard for lung cancer chemotherapy, whatever t...
IntroductionSuperiority of camptothecin regimens over etoposide—both combined with platinum analogs—...
BackgroundDose intensity and dose density of first line Platinum and Etoposide (PE) do not influence...
Background:Irinotecan and cisplatin individually are active in non-small cell lung carcinoma (NSCLC)...
IntroductionWe undertook this phase II study to measure postoperative drug delivery and toxicity of ...
Introduction:A prespecified analysis of the large, randomized, phase III study in advanced non-small...
IntroductionWe conducted a phase II study of combination chemotherapy with irinotecan (CPT) and cisp...
Background:Lung cancer remains a leading cause of cancer-related mortality in North America. Despite...